Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer

Many epidemiological studies have reported an association between breast and prostate cancer. BRCA2 functions as a tumour‐suppressor gene in about 35% of large familial breast‐cancer clusters; its role in the pathogenesis of sporadic breast cancer is less clear. We have evaluated immunohistochemical expression of BRCA2 protein and allelic loss of markers at the BRCA2 locus in tissue derived both from sporadic and from familial cases of prostate cancer. Immunohistochemical analysis was performed in 167 paraffin‐embedded archival specimens. Normal prostate and 75% (120/160) of prostate‐cancer tissue did not express BRCA2 protein. However, 25% (40/160) of cancer cases did express patchy staining; of these, 17% (27/160) expressed positive nuclear staining in normal glandular tissue adjacent to tumour (either in addition to, or, independent of tumour). Allelic loss is the hallmark of a tumour‐suppressor gene. Markers flanking (D13S267, D13S260) and within (D13S171) the BRCA2 gene indicated allelic loss in at least one locus in 23% (17/73) of tumours analyzed. There was no difference in the rates of allelic loss between sporadic and familial tumours, nor was there any association between immunohistochemical staining and allelic loss. Although immunohistochemical staining provided no useful prognostic information, allelic loss at BRCA2 was shown in univariate analysis to be associated with poorer survival (log‐rank test, p = 0.046). Int. J. Cancer 78:1–7, 1998.© 1998 Wiley‐Liss, Inc.

[1]  M. Stratton,et al.  Recent advances in understanding of genetic susceptibility to breast cancer. , 1996, Human molecular genetics.

[2]  K. Cooney,et al.  Distinct regions of allelic loss on 13q in prostate cancer. , 1996, Cancer research.

[3]  M H Skolnick,et al.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. , 1994, Journal of the National Cancer Institute.

[4]  W. Benedict,et al.  Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. , 1994, Cancer research.

[5]  O. Cussenot,et al.  The BRCA2 gene is not relevant to sporadic prostate tumours , 1996, International journal of cancer.

[6]  G. Olafsdóttir,et al.  Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. , 1992 .

[7]  T. Visakorpi,et al.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. , 1995, Cancer research.

[8]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Devilee,et al.  Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. , 1995, British Journal of Cancer.

[10]  V. P. Collins,et al.  Allelotyping of human prostatic adenocarcinoma. , 1991, Genomics.

[11]  M. Stratton,et al.  Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. , 1995, Journal of clinical pathology.

[12]  T. Sellers,et al.  Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. , 1994, Journal of the National Cancer Institute.

[13]  M. Beckmann,et al.  Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. , 1996, British Journal of Cancer.

[14]  J. Gudmundsson,et al.  Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13. , 1995, Cancer research.

[15]  R. Kirby,et al.  Conservation of inflatable penile prosthesis during radical retropubic prostatectomy. , 1997, British journal of urology.

[16]  M. Badzioch,et al.  Familial breast cancer risks. Effects of prostate and other cancers , 1993, Cancer.

[17]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[18]  R. Bookstein,et al.  Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer , 1994, Genes, chromosomes & cancer.

[19]  J. Eyfjörd,et al.  BRCA2 mutation in Icelandic prostate cancer patients , 1997, Journal of Molecular Medicine.

[20]  M. Skolnick,et al.  Low incidence of BRCA2 mutations in breast carcinoma and other cancers , 1996, Nature Genetics.

[21]  W. Benedict,et al.  Changes in growth and tumorigenicity following reconstitution of retinoblastoma gene function in various human cancer cell types by microcell transfer of chromosome 13. , 1992, Cancer research.

[22]  D. Easton,et al.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. , 1995, Oncogene.

[23]  E. U. Thiessen,et al.  Concerning a familial association between breast cancer and both prostatic and uterine malignancies , 1974, Cancer.

[24]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[25]  Sheila Seal,et al.  BRCA2 mutations in primary breast and ovarian cancers , 1996, Nature Genetics.

[26]  Yusuke Nakamura,et al.  Mutation analysis in the BRCA2 gene in primary breast cancers , 1996, Nature Genetics.

[27]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.